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Abstract
Targeting the oestrogen receptor, HER2 (human epidermal growth
factor receptor 2) and vascular endothelial growth factor has
markedly improved breast cancer therapy. New targeted thera-
peutic approaches to induction of apoptosis or inhibition of anti-
apoptosis, cell cycle progression, signal transduction and angio-
genesis are described. The molecular pathways and their inhibitory
or repair mechanisms are discussed in the preclinical and clinical
settings.
Introduction
Treatment of early-stage breast cancer requires a multi-
modality approach to eradicate residual cancer and prevent
recurrent disease. Targeting the pathways that promote or
sustain growth and invasion of carcinoma cells is critical to
effective treatment of breast cancer [1,2].
Targeting the oestrogen receptor (ER) is the oldest molecular
targeted therapy approach, and widespread use of the
selective ER modulator tamoxifen in breast cancer is
responsible for major improvements in cure rates, quality of
life and disease prevention during the past 25 years.
Targeting both HER2 (human epidermal growth factor
receptor 2) with trastuzumab and the vascular endothelial
growth factor (VEGF) with bevacizumab in combination with
chemotherapy has become a further milestone of molecular
targeted therapy [3-5]. However, intrinsic and acquired
resistance to endocrine and/or cytostatic treatments is still a
common feature that limits the benefits of these novel
therapeutic strategies. Therefore, clinical trials of endocrine
or cytotoxic therapies combined with growth factor pathway
inhibitors or their downstream signalling elements are
warranted; such approaches may allow us to improve upon
the current standard of care for breast cancer patients [6].
Unfortunately, despite encouraging preclinical data, some of
these combinations have yielded disappointing results in the
clinical setting [7].
This review describes and critically discusses targeted
therapies for induction of apoptosis or inhibition of anti-
apoptosis, cell cycle progression, signal transduction and
angiogenesis (Fig. 1). Table 1 summarizes both finished and
ongoing studies in this area.
Induction of apoptosis and inhibition of anti-
apoptosis
Apoptosis is a precisely regulated and evolutionarily con-
served programme of cell suicide, which plays important roles
during embryogenesis and immunology. Disturbances in the
physiological programme of apoptosis prolong the life of cells
and thereby promote carcinogenesis. Consequently, apop-
tosis is frequently diminished in cancer cells, supposedly
caused by a dominance of anti-apoptotic proteins in
malignant tumours. Regulation of apoptosis is complex, but
two distinct pathways can be identified: the intrinsic apop-
totic pathway, also referred to as p53-mitochondrial pathway;
and the extrinsic pathway, which is activated through ‘death
receptors’ and their corresponding ligands (for example, the
death-inducing cytokine TRAIL [tumour necrosis factor-
related apoptosis inducing ligand]). TRAIL is a trans-
membrane protein that is cleaved by proteases to release a
soluble form. Although it is constitutively expressed in normal
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Table 1
Clinical studies of targeted therapy with anti-sense nucleotides, antibodies, kinase inhibitors and other agents in breast cancer
Cellular target  Agent Application Clinical study  References
TRAIL receptors TRAIL BC, gynaecologic malignancies Phase I  [9,14]
26S proteasome  Bortezomib Metastatic BC  Phase II  [22]
Bortezomib Metastatic BC  Phase II  [23]
Bortezomib/trastuzumab  Metastatic BC  Phase I  [24]
Bortezomib/capecitabine  Metastatic BC  Phase I/II  [25]
mTOR Everolimus (RAD-001)  Primary BC, neoadjuvant Phase III, GEPARquinto, GBG 44 [88]
Everolimus (RAD-001)  Metastatic BC, bone  Phase II, GBG 41 [89]
metastases
p53 Ad5CMV-p53 and  Primary BC, neoadjuvant Phase II  [42]
docetaxel/doxorubicin 
EGFR Cetuximab and paclitaxel Advanced BC  Phase I  [44]
Erlotinib  Primary BC, neoadjuvant Phase I  [50]
Trastuzumab and capecitabine  BC, beyond progression  Phase II, GBG 26,  [90]
versus capecitabine
EGFR/HER2 Lapatinib and capecitabine  Advanced BC  Phase III [60,61]
versus capecitabine
Lapatinib and paclitaxel  Inflammatory BC, neoadjuvant  Phase II  [62]
Lapatinib and  Primary BC, HER2+,  Phase III, GBG 47, NeoAltto [91]
paclitaxel/trastuzumab neoadjuvant
Lapatinib and trastuzumab  BC, HER2+ Phase III, GBG 46, ALTTO [92]
Ras, farnesyl transferase Tipifarnib and gemcitabine  Metastatic BC  Phase II  [63]
Tipifarnib and letrozole Advanced BC  Phase II  [64]
Lonafarnib and anastrozole  Metastatic BC  Phase II  [63]
COX-2 Celecoxib BC adjuvant Phase III, GBG 27 [93]
VEGF Bevacizumab  Metastatic BC  Phase I/II  [68]
Bevacizumab Metastatic BC  Phase II  [69]
Bevacizumab and vinorelbine Metastatic BC  Phase II  [70]
Bevacizumab and vinorelbine Metastatic BC  Phase II  [71]
Bevacizumab, docetaxel Metastatic BC  Phase II  [72]
Bevacizumab/trastuzumab,  HER-2 positive metastatic BC  Phase II  [73]
carboplatin/nab-paclitaxel 
versus trastuzumab 
carboplatin/nab-paclitaxel 
Bevacizumab, docetaxel Neo-adjuvant, nonmetastatic,  Phase II  [75]
metastatic BC
Bevacizumab doxorubicin/ Neo-adjuvant, inflammatory,  Phase II  [76]
docetaxel locally advanced 
Bevacizumab and capecitabine  Advanced BC  Phase III  [74]
versus capecitabine
Bevacizumab and paclitaxel  Advanced BC  Phase III  [5]
versus paclitaxel
Bevacizumab and trastuzumab HER2+, metastatic BC Phase II [79]
Bevacizumab and docetaxel/ HER2+, recurrent or  Phase III  [80]
trastuzumab versus  metastatic BC
docetaxol/trastuzumab
Bevacizumab and letrozole  BC, advanced and metastatic Phase III, GEICAM/GBG 51 [94]
versus letrozole
Bevacizumab and erlotinib Metastatic BC  Phase II  [81]
Bevacizumab and everolimus Advanced solid tumours  Phase I  [82]
BC, breast cancer; COX, cyclo-oxygenase; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; mTOR,
mammalian target of rapamycin; TRAIL, tumour necrosis factor-related apoptosis inducing ligand; VEGF, vascular endothelial growth factor.Page 3 of 12
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tissue, TRAIL preferentially induces apoptosis, with minimal
adverse effects on normal cells. Therefore, targeting TRAIL
and raising agonistic monoclonal antibodies directed against
TRAIL receptor 1 or 2 have emerged as promising thera-
peutic approaches in cancer [8].
TRAIL receptor activating agents have been found to exhibit
favourable in vitro and in vivo activity in treatment of several
malignancies, including breast and gynaecological cancers.
Preclinical and early phase I studies have provided some
support to the assumption that these novel agents are safe,
with increased target specificity for malignant cells. When
these targeted agents are combined with conventional
chemotherapy drugs or radiotherapy, they appear to increase
cell death over single agent modalities [9] (Table 1).
Mitochondria-mediated apoptosis is regulated through anti-
apoptotic (bcl-2) and pro-apoptotic (bax and bad) proteins of
the bcl-2 family. Over-expression of bcl-2 occurs in 40% to
80% of human breast cancers. Most bcl-2 positive breast
cancers express ER and/or progesterone receptor. This
positive association of bcl-2 with hormone receptors in breast
cancer may explain its apparent correlation with response to
hormonal therapy. However, diminished apoptotic response
caused by bcl-2 over-expression is associated with resis-
tance of tumour cells to cytotoxic drugs. Downregulation of
bcl-2 by antisense oligonucleotides has been shown to
improve the efficacy of chemotherapy in experimental models.
Phase I randomized clinical trials are ongoing in patients with
solid tumours [10] using G3139 (oblimersen sodium), a
phosphorothioate antisense oligodeoxynucleotide that targets
bcl-2 mRNA and downregulates bcl-2 protein translation.
Further studies should examine the molecular effect of the
regimen as well as clinical responses of cancers in which
taxanes are indicated to be beneficial [11].
Inhibitors of apoptosis proteins
Negative regulators called ‘inhibitors of apoptosis proteins’
(IAPs) prevent uncontrolled and excessive cell death in the
final course of apoptotic signalling. An important member of
this group is survivin, which can be detected in approximately
90% of breast tumours. Increased survivin levels are signifi-
cantly associated with high nuclear grade, negative hormone
receptor status, HER2 over-expression, VEGF expression,
and high urokinase-type plasminogen activator and plasmino-
gen activator inhibitor-1 levels. Therefore, patients with
elevated levels of survivin have significantly worse disease-
free survival and overall survival than do patients with lower
levels of survivin. In a multivariate analysis the prognostic
value of survivin in terms of disease-free and overall survival
was found to be independent of both TNM stage and
molecular parameters.
Survivin may be a suitable target in future therapeutic
strategies [12]. Although anti-cancer drugs have been
designed to inhibit the growth of tumour cells, chemotherapy
frequently fails because of the development of multidrug
resistance (MDR). Over-expression of survivin in MCF-7 cells
due to transfection with survivin expression vectors results in
decreasing sensitivity to cytotoxic drugs and activation of P-
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Figure 1
Cell signalling pathways: targets for breast cancer treatment. EGFR, epidermal growth factor receptor; GPCR, G-protein-coupled receptors; HER,
human epidermal growth factor receptor; IKK, inhibitor of NF-κB kinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-κB; TRAIL,
tumour necrosis factor-related apoptosis inducing ligand; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor
receptor.glycoprotein (MDR1), which exports drugs out of cells.
Downregulation of survivin expression in MCF-7/adriamycin-
resistant cells by RNA interference directed against survivin
increased drug accumulation in cells because of inhibtion of
P-glycoprotein. Downregulation of P-glycoprotein expression
with the specific inhibitor verapamil markedly suppressed
survivin mRNA expression, whereas no opposite effect of
upregulated P-glycoprotein has been reported. These
findings suggest that survivin may play a key role in MDR in
the presence of P-glycoprotein, and this may represent a
novel strategy for modulating MDR in cancer cells [13]. LY
2181308 is an antisense molecule directed against survivin
that is already being studied in phase I clinical trials [14,15].
Nuclear transcription factor (nuclear factor-κ κB)
The nuclear transcription factor nuclear factor-κB (NF-κB)
has an anti-apoptotic effect, activating IAPs. NF-κB may also
work in a pro-apoptotic way by regulating ‘interferon-
regulated factor-1’, the oncogene c-myc, p53 and caspase-1.
A preclinical investigation into inhibition of NF-κB via the
synthetic inhibitor PS-1.145 is underway [14]. It is already
known that constitutive activation of NF-κB supports progres-
sion of breast cancer to hormone-independent growth [16]
Furthermore, NF-κB inhibits extracellular signal-regulated
kinase (ERK) activation to enhance cell survival during the
development of tumour adaptive radioresistance [17].
Gemcitabine is a nucleoside analogue that is applied in the
treatment of several solid tumours, including breast carcinoma.
Despite its cytotoxic effect, clinical efficacy is impaired by the
development of resistance. Immunohistochemical analysis of
clinical samples of breast carcinoma validated the belief that
neoadjuvant gemcitabine treatment induces NF-κB expression
and downregulation of inhibitor of NF-κB (IκB). Gene
expression patterns and findings of in vitro functional studies
and analyses of tissue samples are in agreement that NF-κB
plays a role in the induction of resistance to chemotherapy.
These data give support to clinical strategies that combine
gemcitabine with NF-κB inhibitors in breast cancer [18].
Increasing evidence supports a protective role for inhibitor of
differentiation and DNA binding-1 (Jd-1) against anti-cancer
drug induced apoptosis. Jd-1 expression results in increased
number of viable MCF-7 breast cancer cells, reduced bax
expression and enhanced bcl-2 expression, but no change in
bcl-xL expression. Expression of NF-κB is augmented,
whereas expressions of p53 and IκB are reduced. Finally, Jd-1
plays a protective role against taxol-induced apoptosis in
breast cancer cells. Inactivation of Jd-1 is a potential
therapeutic strategy that may inhibit breast cancer progression
and anti-cancer drug resistance [19].
Ubiquitine-proteasome system
The ubiquitine-proteasome system regulates the cell cycle
regulator p53, cyclins and cyclin-dependent kinases (CDKs),
as well as proteins of the bcl family. Inhibitors of the
proteasome system are responsible for the accumulation of
pro-apoptotic proteins (for instance, BAX), delivering cyto-
chrome from mitochondria and thereby activating intrinsic
apoptotic signal transduction.
Inactivation of NF-κB by proteasome inhibition contributes to
increased apoptosis induced by histone deacetylase
inhibitors (HDACis). The HDACis constitute a novel class of
anti-cancer agents that cause growth arrest, differentiation
and/or apoptosis in many tumour cells, and they regulate the
activity of the anti-apoptotic transcription factor NF-κB. The
proteosome inhibitor MG-132 strongly reduces the activity of
NF-κB. Moreover, MG-132 potentiates HDACi-induced cell
death. Induction of the stress-related kinase JNK (c-Jun amino
terminal kinase) and p38, and upregulation of p21 and p27
are also observed after co-treatment of cells with HDACi and
MG-132. Thus, combined treatment with HDACi and
proteasome inhibitors potentiates apoptosis in breast cancer
cells, representing a novel potential therapeutic strategy in
breast cancer [20].
Signalling pathways that converge on two different
transcription factor complexes, NF-κB and activator protein
(AP)-1, have been identified in ER-positive breast cancers that
are resistant to the anti-oestrogen tamoxifen. The model cell
lines (MCF-7/HER2 and BT 474) were treated with the IκB
kinase inhibitor parthenolide or the proteasome inhibitor
bortezomib (PS 341), alone and in combination with tamoxifen.
Furthermore, expression microarray data available from UCSF
node-negative ER-positive breast cancer patients with known
clinical outcome were used to search for potential genes that
signify upregulated NF-κB and AP-1 transcriptional activity in
association with tamoxifen resistance. The association of these
genes with patient outcome was further evaluated using node-
negative ER-positive breast cancer patients identified from
three other published datasets (Rotterdam, Amsterdam and
Basel). Doses of parthenolide and bortezomib that were
capable of sensitizing the two endocrine-resistant breast
cancer models to tamoxifen can suppress NF-κB and AP-1
regulated gene expression in combination with tamoxifen.
Transcript profiles from the UCSF breast cancer cases
revealed three NF-κB and AP-1 upregulated genes (cyclin D1,
urokinase-type plasminogen activator and VEGF) that can
dichotomize node-negative ER-positive cases into early and
late relapsing subsets, despite adjuvant tamoxifen therapy; they
had the greatest ability to predict outcome in younger patients.
Across the four independent sets of node-negative ER-positive
breast cancer cases (UCSF, Rotterdam, Amsterdam and Basel
[21]), high expression of all three NF-κB and AP-1 upregulated
genes was associated with earliest metastatic relapse. These
findings suggest that agents that can prevent activation of
NF-κB and AP-1 genes may prove useful in restoring the
endocrine responsiveness of high-risk ER-positive breast
cancers [21].
Bortezomib is also a potent inhibitor of the 26S proteasome,
with broad anti-tumour activity (Table 1). Twelve patients with
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phase II study [22]. No objective responses were observed,
one patient had stable disease and 11 others experienced
disease progression. The median survival time was 4.3
months. The most common grade 3 or 4 toxicities included
fatigue (58%) and skin rash (33%). Although bortezomib was
well tolerated, it exhibited only limited clinical activity against
metastatic breast cancer when used as a single agent. The
future development of this drug for the treatment of breast
cancer should be guided by in vivo models that optimize
activity in combination with other anti-tumour agents. Similar
clinical experience was reported by Engel and coworkers
[23], who conducted a single institution, phase II study of
bortezomib in the treatment of patients with metastatic breast
cancer. There were no observed objective responses in any
of the 12 patients who received treatment with bortezomib.
Furthermore, all 12 patients progressed while receiving
therapy with bortezomib. The study was terminated after first
stage because of lack of any objective response.
The two agents bortezomib and trastuzumab prevent NF-κB
activation and induce nuclear accumulation of the CDK
inhibitor p27kip1, suggesting that combining bortezomib with
trastuzumab could increase the efficacy of trastuzumab.
Bortezomib induced apoptosis in HER2-positive (SKBR-3,
MDA-MB-453, HER2 transfected MCF-7) and HER2-
negative breast cancer cells (MCF-7) in a dose-dependent
and time-dependent manner. Sequential treatment (trastuzu-
mab then bortezomib) induced either necrosis or apoptosis,
depending on the trastuzumab pre-incubation time. The
addition of bortezomib to trastuzumab increases the effect of
trastuzumab in HER2-positive cell lines in a synergistic way.
This effect probably results from the ability of these two drugs
to target the NF-κB and p27 pathways. The potential clinical
application of this drug combination is currently under
evaluation in a phase I clinical trial [24].
A phase I/II including 35 patients [25] was recently conduc-
ted to evaluate the combination of capecitabine and
bortezomib in anthracycline-pretreated and/or taxane-pre-
treated patients with metastatic breast cancer. The treatment
was generally well tolerated and associated with toxic effects
that were consistent with the known side effects of the
individual agents. The intent-to-treat overall response rate
was 15%, and an additional 27% of patients had stable
disease. Median time to progression and overall survival were
3.5 months and 7.5 months, respectively. The median dura-
tion of response was 4.4 months. Although bortezomib and
capecitabine are well tolerated, the combination had only
moderate anti-tumour activity in heavily pretreated patients.
Phosphatidyl-inositol 3-kinase
Phosphatidyl-inositol 3-kinase (PI3K) plays an important role
in survival, proliferation, motility and neoangiogenesis in
cancer cells. As a consequence of dysregulation of the cell
cycle, PI3K is over-expressed and activates Akt, which -
through phosphorylation of NF-κB, bad and caspase 9 - has
anti-apoptotic influences. Also, epidermal growth factor
receptor (EGFR), as well as HER2, activate PI3K and
enhance cell growth via Akt.
Preclinical data identified a possible role for the PI3K/Akt
pathway in docetaxel-induced apoptosis. Specifically, inhi-
bition of one of the three isoforms of Akt, namely Akt 2, by the
PI3K inhibitor LY294002 counteracted the activity of fibro-
nectin to protect cells from apoptosis induced by docetaxel.
Further investigations showed that Akt 2 activation protects
against docetaxel-induced apoptosis by regulating survivin
levels in a PI3K-dependent manner. Targeting the PI3K/Akt 2
pathway might be a promising strategy for enhancing
sensitivity to docetaxel in breast cancer [26]. Inhibition of the
PI3K/Akt pathway improves response of long-term
oestrogen-deprived breast cancer xenografts to anti-
oestrogens. The combination of wortmannin with tamoxifen or
fulvestrant inhibited tumour growth of long-term oestrogen-
deprived aromatase-transfected human ER-positive breast
cancer cells (UMB-1Ca) better than did either drug alone.
The combination of wortmannin plus fulvestrant was the most
effective treatment, maintaining tumour regression for a
prolonged period. These data suggest that blocking both ER
and growth factor receptor pathways could provide effective
control over tumour growth in long-term oestrogen-deprived
human breast cancers [27]. Further data reveal that loss of
the PTEN gene (which encodes a phosphatidylinositol phos-
phatase, and therefore is a negative regulator of PI3K
function) results in constitutive activation of the PI3K pathway
and poor patient outcome [28]. The study indicates that
aberrant PI3K pathway signalling is strongly associated with
metastasis and poor survival, supporting the contention that
inhibition of this pathway could improve prognosis.
The protein mammalian target of rapamycin (mTOR) is
activated downstream by phosphorylated Akt. Thereby,
mTOR promotes cancer cell proliferation, maintains blood
and nutrient supply by neoangiogenesis, promotes tumour
spread and metastasis, and inhibits cancer cell apoptosis.
Inhibiting mTOR with the new drug CCI-779
(temsirolimus), which negatively influences these functions,
is already being investigated in clinical studies. HER2 and
PI3K pathway inhibitors were tested for their ability to
inhibit breast cancer cell growth and tumour development
in 20 human breast cancer lines [29]. In that study,
rapamycin combined with trastuzumab was found to
increase anti-tumour efficacy significantly in comparison
with trastuzumab alone in HER2-over-expressing breast
cancer cells. Rapamycin and trastuzumab significantly
reduced levels of cyclins D1 and D3 and increased the
cleavage of caspase 3, suggesting increased apoptosis.
These findings suggest that rapamycin combined with
trastuzumab has an enhanced anti-cancer effect, and this
combination could be developed as an improved thera-
peutic regimen in breast cancer.
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primary breast cancer integrating mTOR antagonist evero-
limus (RAD001), bevacizumab and lapatinib in the neo-
adjuvant setting (GeparQuinto), and a randomized
discontinuation phase II study to determine the efficacy of
everolimus (RAD001) in breast cancer patients with bone
metastases (RADAR; Table 1).
Cell cycle inhibition and cyclin-dependent
kinase inhibitors
Interactions of cyclins with CDKs play an important role in
regulating the cell cycle. CDKs promote phosphorylation of
their target proteins, initiating progression of the cell cycle.
Because cells begin to undergo cell division through
mitogenic stimuli, there is induction of synthesis of cyclin D1,
which is associated with the kinases CDK4 as well as CDK6.
Cyclin D1 is essential for HER2-induced cell growth and is
induced by growth factors through Ras-dependent and Ras-
independent signalling pathways.
In a preclinical study [30], the CDK inhibitor flavopiridol was
combined with several transduction inhibitors (cyclo-oxyge-
nase-2 inhibitor SC236, protein kinase C kinase inhibitor, and
PI3K inhibitor LY294002). In two breast cancer cell lines, one
HER2 low expressing and another HER2 high expressing
(MCF/neo and MCF/18, respectively), enhanced growth
inhibition was observed predominantly in the high HER2
expressing cell line. These data suggest that combinations of
flavopiridol and signal transduction inhibitors warrant further
studies as treatments for breast tumours, and that HER2
expression may influence the choice of inhibitor to combine
with flavopiridol.
Exposure of MCF-7 cells to adriamycin, taxol, or UVB
results in fourfold to fivefold increased expression of
survivin. Inhibition of survivin phosphorylation by flavopiridol
resulted in loss of survivin expression, and nonphos-
phorylatable survivin exhibited accelerated clearance [31].
Treatment with flavopiridol caused accumulation in the G1
phase of the cell cycle and induced apoptosis in breast
cancer cell lines (SKBR-3 and MB-468). This was asso-
ciated with downregulation of the levels of cyclins D1 and
B1, and with inhibition of CDK1, CDK2 and CDK4. In MB-
468 cells exhibiting over-expression of bcl-2, apoptosis was
inhibited. Sequential treatment with a nontaxane tubuline
polymerizing agent epothilone (Epo B) followed by
flavopiridol induced significantly more apoptosis of MB-468
cells than treatment with the reverse sequence or treatment
with either agent alone [32]. These findings suggest that
the superior sequence-dependent anti-breast cancer
activity of EpoB followed by flavopiridol may be due to
flavopiridol-induced bax conformational change and
downregulation of the anti-apoptotic IAP bcl-xL and Mcl-1
proteins, but this treatment may not overcome the
resistance to apoptosis of breast cancer cells conferred by
over-expression of bcl-2.
Human breast cancer cell lines, which express high levels of
endogenous HER2 receptor, were treated with trastuzumab
together with flavopiridol [33]. The combination syner-
gistically inhibited DNA synthesis, cellular proliferation and
contact-dependent growth. In SKBR3 cells, the combination
of trastuzumab and flavopiridol inhibited the Ras/mitogen-
activated protein kinase (MAPK)/Akt pathway, and decreased
cyclin D1 abundance and kinase activity to a greater extent
than either drug alone. Compared with single-agent
treatment, combination treatment selectively inhibited Akt and
RB1 phosphorylation. Cyclin D1 over-expression reverses
drug treatment induced cell cycle arrest. Inhibition of Akt may
prove to be a useful therapeutic strategy in combination with
flavopiridol for HER2-positive tumours.
A mRNA expression signature including EGFR was found to
predict response to the combination of trastuzumab and
flavopiridol in array analysis [34]. Three lines of evidence
support the contention that EGFR is a potential target of
flavopiridol-trastuzumab synergy: EGFR protein was rapidly
and completely lost after combination treatment; a cell line
that expresses amplified levels of both HER2 and the EGFR
was resistant to the combined drugs; and treatment with EGF
prevented any therapeutic effects of flavopiridol and
trastuzumab, either singly or in combination. The data clearly
demonstrate that the interaction between HER2 and EGFR is
not sufficiently addressed in targeted and combination breast
cancer therapies [2] and should be studied extensively. In
recent phase I clinical trials, flavopiridol has shown some
promise in the treatment of a variety of human tumours.
However, because of the severe toxicity observed, the use of
less toxic doses in combination with other antiproliferative
agents, as reported above from in vitro experiments, would
be desirable. Consequently, phase I studies are underway to
determine the toxicities and characterize the pharmaco-
kinetics of docetaxel and flavopiridol in patients with meta-
static breast cancer [35].
p53: a target for gene therapy
The p53 gene acts as a regulator of cell growth and DNA
repair in normal cells; inactivation of the gene appears to lead
to cancer. It is the most frequently mutated gene in human
cancers; 35% of breast tumours have p53 mutations, of
which 88% are located within exons 5 to 8 [36]. Mutations in
the p53 gene occur more frequently in ER-negative, basal-like
and HER2-amplified tumours than in luminal, ER-positive
breast tumours [37]. p53 mutations occur in 24.5% of the
axillary node-negative breast carcinomas and more frequently
in cancers with HER2 amplification (38.9% versus 20.9% in
those without HER2 amplification). Elevated risks for disease
recurrence and mortality were identified in patients with both
p53 mutation and HER2 amplification [38].
p53 mutations may help to identify a subset of very high risk
breast cancer patients with worse prognosis [39]. To
investigate the effect of specific inhibition of mutated p53
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mutation were transfected with antisense RNA using a
cationic liposome-mediated method. Forty-eight hours after
transfection, the antisense RNA (Asp53 exon 8’RNA) had a
significant retarding effect on p53-related proliferation
inhibition, along with a decrease in p53 protein expression.
Such an approach may be used as a therapeutic option in
human malignancy [40]. Cells expressing p53 mutations are
either more sensitive to cisplatin and melphelan or more
resistant than untransfected cells, depending on the
mutation. However, there is no difference in response to
daunorubicin treatment. These data also suggest that the
nature of the p53 mutation influences sensitivity to cytotoxic
drugs [41].
Intratumoural administration of a nonreplicating adenoviral
vector (Ad5) that contains the human wild-type p53
(Ad5CMV-p53) combined with chemotherapy could increase
the efficacy of primary systemic chemotherapy (PST) as
measured by pathological complete response (pCR) in the
management of patients with locally advanced breast cancer
(Table 1). In a prospective, open label, phase II trial [42], 13
patients with locally advanced breast cancer were treated
with six 3-week cycles of PST, which consisted of intra-
tumoural injections of Ad5CMV-p53 for 2 consecutive days
plus docetaxel and doxorubicin followed by surgery. The trial
was terminated early because none of the patients achieved
pCR. Eight patients (73%) had a p53 mutation; serial
biopsies showed increases in p53 mRNA and p21 (WAF1/
Cip1 mRNA). All 12 evaluable patients achieved an objective
clinical response. Surgical specimens revealed scattered
tumour cells with extensive tumour infiltrate leucocytes,
predominantly T lymphocytes. There was no increase in
systemic toxicity. Ad5CMV-p53 combined with PST was
safe, active and associated with local immune modulatory
effects. The promising clinical activity of this combination
deserves further investigation in randomized studies.
Monoclonal antibodies and tyrosine kinase
inhibitors for EGFR and HER2
EGFR, HER2, HER3 and HER4 are members of the ErbB
family of receptor thyrosine kinases. EGFR and HER2 are
over-expressed in a variety of human tumours, and over-
expression generally correlates with poor prognosis and
decreased survival. Three of the four receptors comprise an
extracellular amino-terminal domain to bind corresponding
ligands (for example, EGF to EGFR; ligands to HER2 are
not known) and an intracellular carboxyl-terminal domain
lodging a tyrosine kinase with the exception of HER3.
Binding of ligands induces dimerization of the receptor and
activation of the kinase through autophosphorylation,
stimulating PI3K/Akt and/or MAPK signalling, various
transcription factors (such as STAT-3, c-fos and ELK-1) and
enhanced production of VEGF. Proliferation, migration,
adhesion and angiogenesis are favoured, whereas
apoptosis is inhibited [43].
From 15% to 30% of breast cancers have been shown to
express high levels of EGFR and HER2. Moreover, hormone-
resistant disease is associated with an inreased expression of
both EGFR and EGFR ligands. Therefore, EGFR and its
downstream signalling pathways are promising anti-tumour
targets.
Cetuximab, an IgG1 chimeric monoclonal antibody, competes
with ligand binding to the EGFR ectodomain, resulting in an
efficient blockade of the tumour-promoting downstream
signalling pathway. Preclinical studies have indicated a
synergistic effect for the combination of anti-EGFR therapy
plus paclitaxel in breast cancer models (Table 1). The
feasibility of this combination was evaluated in a dose-
escalation phase I trial using cetuximab/paclitaxel in patients
with metastatic breast cancer [44]. Treatment consisted of
weekly cetuximab therapy and paclitaxel given every 3 weeks,
with dose escalation of cetuximab until the maximum
tolerated dose was reached. Twelve patients were enrolled
into three treatment cohorts. Two out of six patients in the
second cohort (cetuximab 100 mg/m2) developed dose-
limiting toxicities, presenting as grade 3 rash. In the third
cohort (cetuximab 100 mg/m2 and paclitaxel in a weekly
schedule), one out of three patients developed grade 3 skin
toxicity. Of 10 patients evaluable for response, two experi-
enced stable disease and eight had disease progression.
Because of prohibitive dermatological toxicity and disappoin-
ting preliminary efficacy, this combination of paclitaxel/
cetuximab was not considered promising.
ZD 1839 (gefitinib) is an example of an orally active, selective
EGFR tyrosine kinase inhibitor, which has shown extensive
preclinical activity. Gefitinib has exhibited in vitro activity as
both monotherapy and in combination with other agents such
as paclitaxel and doxorubicin, inhibiting the growth of breast
cancer cells that are resistant to endocrine agents such as
tamoxifen [45].
To test whether continous or pulsatile inhibition of EGFR
signalling is effective in inhibiting tumour proliferation, combi-
nations of paclitaxel and gefitinib, using either intermittent or
continous dosing schedules, were compared in mice [46]. In
combination with paclitaxel, pulsatile gefitinib was
significantly superior to continous dosing. When gefitinib was
administered for 1 or 2 consecutive days before paclitaxel,
much higher doses could be given safely. Two days of
gefitinib treatment before paclitaxel was most effective,
causing significantly greater mean tumour regression and
higher percentage of complete responses than other
schedules.
Preclinical studies conducted in human ductal carcinoma in
situ (DCIS) xenografts in nude mice suggest a potential role
for EGFR inhibitors. Gefitinib has been shown to produce a
response in DCIS through a decrease in epithelial prolifera-
tion. These findings indicate that tyrosine kinase inhibitor
Available online http://breast-cancer-research.com/content/10/4/211
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chemoprevention of DCIS [47] (Table 1).
The spontaneous pulmonary metastasis mouse model was
applied to evaluate the ability of the EGFR TKI erlotinib
(OSI-774) to prevent pulmonary metastasis in curatively
resected breast carcinoma [48,49]. The expression levels of
EGF and EGFR were significantly higher in pulmonary
metastatic nodules than in primary breast cancer tissue.
Treatment of erlotinib given to mastectomized mice inhibited
the incidence of pulmonary metastases. The number of
metastatic pulmonary nodules was significantly reduced in
the erlotinib-treated group compared with the control. The
effects of treatment with erlotinib for 6 to 14 days was
evaluated in a presurgical study conducted in 41 patients
with breast cancer of stage I to III [50]. Grade 2 rash and
diarrhoea were the main toxicities. Erlotinib inhibited tumour
cell proliferation (Ki-67), and phosphorylation of EGFR and
HER2. Treatment was associated with significant reductions
in phosphorylated MAPK and Akt in ER-positive cancers.
Inhibition of proliferation occurred in ER-positive but not in
HER2-positive or triple-negative carcinomas.
Trastuzumab, a humanized monoclonal antibody that targets
HER2, is of special importance in breast cancers that over-
express HER2. When combined with standard cytotoxic
chemotherapy, trastuzumab improves the outcome and
survival in patients with metastatic disease [3]. Furthermore,
over the past 3 years, studies incorporating trastuzumab in
sequence or concurrently with taxane-based chemotherapy in
the adjuvant setting have demonstrated considerable benefit
in this subset of patients, and longer term findings regarding
outcomes and late toxicity are expected during the next few
years [51-55] (Table 1). Based on these impressive results,
trastuzumab represents the standard of care in the adjuvant
treatment of HER2 over-expressing breast cancers. The role
of trastuzumab in the neoadjuvant setting is very promising
but must be further evaluated in larger prospective
randomized trials [56].
However, there is still a large proportion of patients over-
expressing HER2 who do not respond to trastuzumab.
Results from a gene expression analysis indicated that lower
expression of genes involved in CD40 signalling is
associated with a greater risk for residual cancer after
trastuzumab-containing preoperative chemotherapy [57]. The
optimal combination of trastuzumab with other agents
requires further evaluation this patient cohort. The role of the
novel antibody pertuzumab remains to be defined in breast
cancer lacking HER2 amplification [58].
Heterodimerization, compensatory crosstalk and redundancy
exist in the HER2/EGFR network, which provides a sound
scientific rationale for dual inhibition of EGFR and HER2.
Trials of approved agents in combination, for example
trastuzumab and cetuximab, are underway. Preclinical studies
conducted in cell lines (MCF-7/HER2 and BT474) showed
that combined treatment with gefitinib, trastuzumab and
pertuzumab in order to block signals from all HER
homodimers and heterodimers inhibits growth of HER2 over-
expressing xenografts significantly better than single agents
and dual combinations [59]. There is also a new generation
of small-molecule TKIs and monoclonal antibodies that target
two or more ErbB receptors (Table 1). Lapatinib, a TKI of
EGFR and HER2, has shown clinical benefit in trastuzumab-
refractory breast cancer and is now approved by the US
Food and Drug Administration [60]. A phase III trial
demonstrated that lapatinib plus capecitabine is superior to
capecitabine alone in women with HER2-positive advanced
breast cancer that progressed after prior therapy including
trastuzumab [61]. The addition of lapatinib prolonged time to
progression significantly and resulted in a trend toward
improved overall survival and fewer patients with central
nervous system involvement at first progression. However,
extracellular domain HER2 (HER2 ECD) baseline serum did
not predict benefit from lapatinib. Paclitaxel monotherapy in
combination with lapatinib could be a successful approach to
managing inflammatory advanced breast cancers patients,
because this type of breast cancer most commonly expresses
EGFR and/or HER2 [62]. In a neoadjuvant phase II study, a
clinical response rate of 77% (complete and partial
responses) and a pCR of 17% were achieved in HER2-
positive tumours. Eighty per cent of EGFR-positive patients
exhibited a response.
Farnesyltransferase inhibitors
The Ras protein regulates genes that are involved with
transcription, translation, cell growth, cell survival and cellular
interactions, as well as development of the cytoskeleton.
Because the gene is mutated in 30%, the regulation of Ras
appears to be a further rational anti-tumour strategy.
Activation of Ras is induced by farnesyl transferase
(‘farnesylation’). In preclinical studies inhibition of breast
cancer cell growth through some farnesyl transferase
inhibitors has been confirmed. The efficacy of the oral
inhibitors tipifarnib and lonafarnib is currently being examined
in phase II studies [63]. However, preliminary findings from
randomized controlled studies are rather disappointing.
Tipifarnib combined with letrozole did not show any benefit
compared with letrozole alone [64].
Targeting tumour neoangiogenesis: 
VEGF and VEGF receptor
Tumour-associated macrophages (TAMs) are associated with
tumour progression and metastasis. Pro-angiogenic factors
were detected as being released by TAMs such as
transforming growth factor-β, tumour necrosis factor-α, matrix
metalloproteinase-9 and VEGF [65]. Besides, legumain (a
member of the asparginyl endopeptidase family) is over-
expressed by TAMs and provides a therapeutic target
molecule. In murine models of metastatic breast, colon and
non-small-cell lung cancers, legumain-based DNA vaccine
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dramatically reduced their density in tumour tissue and
resulted in a marked decrease in angiogenesis.
VEGF has emerged as a key target in the treatment of
cancer. As the ligand to the VEGF receptor, it plays a central
role in promoting tumour angiogenesis. Over-expression of
VEGF leads to poor outcomes in patients with breast cancer
and other tumours. Preclinical studies have shown that the
humanized monoclonal antibody to VEGF bevacizumab can
reduce tumour angiogenesis and inhibit the growth of solid
tumours, either alone or in combination with chemotherapy
[66,67]. A phase I/II dose escalating study in previously
treated metastatic breast cancer [68] identified an overall
response rate of 6.7% and a median duration of response of
5.5 months. Four of the 75 patients included experienced
adverse events such as hypertensive encephalopathy,
nephrotic syndrome and headache combined with nausea and
vomiting, and therefore discontinued therapy. In a randomized
phase II trial with single-agent bevacizumab at two dosages in
35 patients with pretreated metastatic breast cancer, one
patient in the high dose arm (10 mg/kg) was shown to have a
complete response [69]. In combination with established
chemotherapies, such as vinorelbine [70,71], docetaxel [72],
carboplatin and nab-paclitaxel [73], use of bevacizumab has
yielded more encouraging results in phase II clinical trials in
patients with refractory metastatic breast cancer.
In a randomized phase III trial conducted in heavily pretreated
breast cancer patients [74], the addition of bevacizumab to
capecitabine resulted in a significant increase in response
rates (19.8% versus 9.1%) and was well tolerated. However,
this did not translate into improved progression-free survival
(4.86 months versus 4.17 months) or overall survival
(15.1 months versus 14.5 months). However, in an open-
label, randomized phase III trial [5], initial therapy for
metastatic breast cancer with paclitaxel plus bevacizumab
significantly prolonged progression-free survival (11.8 months
versus 5.9 months), but not overall survival (26.7 months
versus 25.2 months), as compared with paclitaxel alone.
Unfortunately, adverse events were more frequent in patients
receiving paclitaxel plus bevacizumab. However, bevacizu-
mab as first-line therapy in metastatic breast cancer is under
investigation in a confirmational phase III trial that is currently
taking place in Europe (AVADO trial).
In the neoadjuvant setting bevacizumab has already been
evaluated. In a first study 34 patients with nonmetastatic and
metastatic unresectable breast tumours exhibited five
complete clinical responses and 24 partial responses [75]. In
another neoadjuvant trial [76] patients with inflammatory and
locally advanced breast cancer received bevacizumab alone
for the first cycle followed by six cycles of bevacizumab with
doxorubicin and docetaxel. After completion of preoperative
chemotherapy, eight out of 13 patients exhibited confirmed
partial responses [76].
Konecny and coworkers [77] measured HER2 and VEGF
levels in primary breast tumour tissue from 611 patients and
found a positive association between their expression levels
and a correlation between increased HER2/VEGF levels and
worse clinical outcomes. In a phase I study initiated by
Pegram and colleagues [78], they assessed the optimal dose
schedule and safety of bevacizumab in combination with
trastuzumab; this was the first trial to test a combination of
multiple monoclonal antibodies in humans. Pharmacokinetic
data from this study suggested that the combination did not
alter the pharmacokinetics of either agent. The response rates
and the tolerable safety profile of this study led to a phase II
extension to evaluate this combination as first-line treatment
for HER2-positive metastatic breast cancer [79]. Studies to
test this combination are currently being performed, including
a randomized, open-label, phase III study with trastuzumab
plus a taxane with or without bevacizumab in HER2-positive
locally recurrent or metastatic breast cancer [80]. Further
investigations are evaluating the combination of bevacizumab
and erlotinib [81] and combination therapy with bevacizumab
and the mTOR inhibitor everolimus [82].
Future trials should not just focus on the combination partner;
the timing of administration is also of major importance.
Because tumour angiogenesis occurs in a very early stage of
carcinogenesis, there is a strong rationale for earlier use of
bevacizumab in the adjuvant setting [83].
Conclusion
Treatments of breast cancer continue to evolve rapidly. New
scientific and clinical achievements are constantly changing
the standard of care and have already led to substantial
reductions in breast cancer mortality. Despite encouraging
preclinical data, some of the molecular targeted agents
(‘biologicals’) have yielded low response rates in the clinical
setting [7]. A further issue is the successful management of
side effects of these agents, such as acneform rash with anti-
EGFR therapy, cardiac insufficiency with trastuzumab treat-
ment, and hypertension and cerebrovascular ischaemia with
bevacizumab therapy. New opportunities to select the right
patient for a benefical therapy has resulted from knowledge
of most of the genes in the human genome and the
development of whole-genome gene expression analysis by
array technology. Many studies have been performed and are
still underway whose aim is to achieve improved matching of
effective drug(s) to the molecular characteristics of the
individual cancer patient [84-86]. Further studies must
provide much needed data on predicting response to
targeted therapies, revealing the mechanisms of resistance to
such therapies and maximizing the patient’s benefit [87].
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